Acute Effects of Zynamite® S in Cognitive Function and Mood

Nektium Pharma

Status: Completed

Conditions: Mood; Cognitive Performance

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Zynamite® S

Study type: Interventional

Funder types: Industry; Other

Identifiers

NCT07126717

ZYNS_HCT_2025.01

Details and patient eligibility

About

The present study sought to confirm the cognitive and mood benefits of a standardized soluble mango leaf extract, named as Zynamite® S. A placebo or a single dose of the botanical extract (100 mg) was administered and its acute effects on mental function and mood were evaluated before product intake, at 30 min, 3 h, and 5 h post-ingestion.

Full description

The present study is a double-blind, randomized, placebo-controlled crossover clinical trial that aimed to evaluate the effects of a standardized soluble mango leaf extract (Zynamite® S) on cognitive performance and mood. The study included 88 healthy university students aged 18-25 years. Participants received a single 100 mg dose of Zynamite® S or a placebo. Cognitive performance was evaluated by using the Trail Making Test (TMT) to assess executive functions, the Digit Symbol Substitution Test (DSST) for processing speed, and the Stroop Color and Word Test and the Stroop Interference Test to evaluate selective attention and cognitive flexibility. Additionally, mood was assessed using the Spanish short version of the Profile of Mood States (POMS). All the assessments were conducted before product intake, at 30 min, 3 h, and 5 h post-ingestion.

Enrollment: 88 patients

Sex: All

Ages: 18 to 25 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Being registered as an undergraduate or postgraduate university student
• Being between 18 and 25 years old
• Being healthy and free of any relevant medical condition or illness

Exclusion criteria

• Suffering from chronic diseases such as asthma, type 1 diabetes, thyroid diseases (such as hypothyroidism or hyperthyroidism), autoimmune disorders (such as Crohn's disease), and psychiatric conditions such as anxiety disorders, major depression, eating disorders (anorexia, bulimia), attention deficit hyperactivity disorder (ADHD), among others
• Being pregnant or lactating
• Having any known intolerance, hypersensitivity, or allergies to any of the ingredients of the investigational products
• Having intestinal malabsorption problems, as well as learning difficulties, dyslexia, eye problems, or color blindness
• Intaking of psychoactive substances or medications that could influence the study results, such as consuming >500 mg of caffeine per day (>6 cups of 150 ml filtered coffee) and/or alcohol
• Having comprehension or communication difficulties that prevent full understanding of the informed consent or effective participation in the study, such as autism spectrum disorders, aphasia, or intellectual disability

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

88 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Capsule containing food-grade maltodextrin

Treatment:

Dietary Supplement: Placebo

Zynamite® S 100mg

Experimental group

Description:

Capsule containing 100 mg of soluble mango leaf extract (Zynamite® S) standardized to 60% of mangiferin

Treatment:

Dietary Supplement: Zynamite® S